Clinical trial
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
NCT00017394 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00017394 |
|---|---|
| Title | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer |
| Official title | A Phase II Study of Bevacizumab in Combination With Vinorelbine in Stage IV Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | bevacizumab, vinorelbine tartrate, laboratory biomarker analysis |
| Enrollment | 56 |
| Start date | Mar 1, 2001 |
| Primary completion | Sep 1, 2007 |
| First posted | Jun 12, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: